Blog

Patrick Forde: Great day for lung cancer care

Patrick Forde/Facebook

Feb 22, 2025, 15:54

Patrick Forde: Great day for lung cancer care

Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, reshared a post by Bristol Myers Squibb on X, adding:

“Great day for lung cancer care!

Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer!”

Quoting Bristol Myers Squibb‘s post:

“MEDIA:

Announcing the final analysis of OS from the CheckMate -816 trial evaluating our immunotherapy used in combination with chemotherapy regimen as neoadjuvant treatment of resectable non-small cell lung cancer.”

Patrick Forde: Great day for lung cancer care

Bristol Myers Squibb cancer CheckMate -816 trial chemotherapy fight against cancer Global fight against cancer immunotherapy Johns Hopkins University Lung cancer non small cell lung cancer NSCLC OncoDaily Oncology Patrick Forde Sidney Kimmel Comprehensive Cancer Center

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial